Search the Newsreel

Equities Analysts Offer Predictions for NAMS FY2027 Earnings

HC Wainwright has lowered its FY2027 EPS forecast for NewAmsterdam Pharma (NASDAQ:NAMS) to $2.15, down from $2.36, while maintaining a "Moderate Buy" consensus rating for the stock with an average price target of $49.33. The company recently reported a quarterly loss of $0.52 per …

NewAmsterdam Pharma grants 28,000 inducement share options at $27.79 to new hires

NewAmsterdam Pharma has issued inducement equity awards to three new non-executive hires under its 2024 Inducement Plan. These awards include share options for 28,000 ordinary shares with an exercise price of $27.79 and restricted stock units for 8,200 ordinary shares. The options vest over …

Damara (DMRA): Lori Firmani plans sale of 1,800 common shares via Maxim

Lori Firmani has filed a notice to sell up to 1,800 shares of Damara (DMRA) common stock through Maxim Group on the NASDAQ, with an aggregate value of $55,980.00 and an anticipated sale date of August 5, 2026. These shares are related to options …

Three New Hires Receive Stock Awards With Up to 4-Year Vesting

NewAmsterdam Pharma has granted inducement equity awards to three new non-executive hires, consisting of 28,000 share options and 8,200 restricted stock units (RSUs). The share options have an exercise price of $27.79 and vest over four years, while the RSUs vest over three years …

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma announced that its Compensation Committee approved inducement grants under Nasdaq Listing Rule 5635(c)(4) for new hires. These grants include share options for 28,000 ordinary shares and restricted stock units for 8,200 ordinary shares, both intended to incentivize new non-executive employees to join …

(NAMSW) Volatility Zones as Tactical Triggers

This article provides an AI-generated analysis of Newamsterdam Pharma Company N.v. Warrant (NASDAQ: NAMSW), focusing on volatility zones as tactical triggers for trading. It outlines institutional trading strategies tailored to different risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe …

FGNX Q2'26 Earnings: revenue estimate is 700.00K USD

FG Nexus Inc. (FGNX) is projected to announce its Q2'26 earnings on August 13, with an estimated revenue of $700,000 and an anticipated EPS of -$6.45. The article provides a detailed table comparing reported and estimated revenue and EPS figures for several quarters, along …

FMR LLC and Abigail Johnson report 10.3M-share Pharma Company NV (NAMS) stake

FMR LLC and Abigail P. Johnson have reported a significant ownership stake in NewAmsterdam Pharma Co N.V. (NAMS), collectively holding 10,339,663 shares of common stock, which represents 8.8% of the class as of June 30, 2026. FMR LLC has sole voting power over 10,329,760 …

Damora Begins Testing Antibody Designed for Monthly Doses

Damora Therapeutics has initiated a global Phase 1/1b clinical trial (CLARITY-101) for DMR-001, an investigational monoclonal antibody targeting mutant calreticulin (mutCALR) in patients with essential thrombocythemia and myelofibrosis. Preclinical data showed DMR-001 has high binding affinity and a longer half-life, supporting once-monthly subcutaneous dosing. …

Damora Therapeutics, Inc. Common Stock (DMRA) FDA Approvals, PDUFA Dates & Drug Alerts 2026

Damora Therapeutics, Inc. (DMRA) has not received any FDA approvals in the past two years, but its drug DMR-001 is currently under FDA review. The company recently announced the initiation of the global Phase 1/1b CLARITY-101 clinical trial for DMR-001, an investigational monoclonal antibody …

NewAmsterdam Pharma Co N.V. Q2 2026: Revenue $3.7M, EPS $(0.52) — 10-Q Summary

NewAmsterdam Pharma Co N.V. (NAMS) reported a significant decline in Q2 2026 revenue to $3.7M from $19.1M year-over-year, alongside a widened net loss of $64.1M, or $0.52 diluted EPS. This downturn is attributed to lower partner-derived receipts after a one-time 2025 development installment and …

NewAmsterdam Pharma (NASDAQ:NAMS) Announces Quarterly Earnings Results

Press Release: NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

NewAmsterdam Pharma provided a corporate update and reported its second quarter financial results. The company highlighted recent achievements and ongoing clinical trials, offering insights into its financial position and future strategic directions. This update serves to inform stakeholders about the company's progress and performance.

NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears

NewAmsterdam Pharma outlined its strategy for obicetrapib, emphasizing the ongoing PREVAIL cardiovascular outcomes trial and commercial preparations for a potential European launch. The company expects to reach its interim event target for the PREVAIL trial by year-end, with an independent review in Q1 2027. …

Damora Therapeutics earnings on deck as rare blood cancer race heats up

Damora Therapeutics is set to release its second-quarter earnings, with analysts expecting a loss of 44 cents per share. The pre-revenue biotech is advancing its lead rare blood cancer treatment, DMR-001, towards clinical trials, facing competition from Incyte Corp.'s INCA033989. Investors will focus on …

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates

NewAmsterdam Pharma Company N.V. (NAMS) reported a Q2 loss of $0.52 per share, missing the Zacks Consensus Estimate of a $0.48 loss, and revenues of $3.7 million, falling short of estimates by 45.41%. The company has underperformed the S&P 500 this year, with its …

NewAmsterdam Pharma Company N.V. reports results for the quarter ended June 30 - Earnings Summary

NewAmsterdam Pharma Company N.V. has reported its financial results for the quarter ended June 30. The earnings summary was provided by Refinitiv and featured on TradingView News. The full article content is behind a paywall requiring a subscription to TradingView for unlimited access.

NewAmsterdam Pharma (Nasdaq: NAMS) June-quarter loss widens; cash $678M

URW SE - Information on total number of voting rights and shares in the share capital as at July 31, 2026

Unibail-Rodamco-Westfield SE Paris, August 3rd, 2026 Information on total number of voting rights and shares in the share capital as of July 31st, 2026 (Article L.233-8-II of the French Commercial Code and Article 223-16 of the General Regulation of the AMF) Date Total number …

NewAmsterdam Pharma (NAMS) On EU Backing Is The Pullback Leaving Shares Mispriced

(NAMS) and the Role of Price-Sensitive Allocations

This article analyzes Newamsterdam Pharma Company N.v. (NASDAQ: NAMS), highlighting weak near and mid-term sentiment that could challenge its long-term positive outlook. The analysis provides AI-generated institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and …

Janus Henderson Group PLC Sells 82,739 Shares of NewAmsterdam Pharma Company N.V. $NAMS

Janus Henderson Group PLC reduced its stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 3.5% in the first quarter, selling 82,739 shares but retaining 2.26 million shares valued at $72.3 million. Despite this sale, institutional investors hold a significant 89.89% of the company, and …

NAMS|NewAmsterdam Pharma Company NV|Price:27.802|Chg%:-0.658

NewAmsterdam Pharma Company NV (NAMS) shows strong fundamentals and high growth potential, despite recent weak stock performance. The company's valuation is considered fair within the Biotechnology & Medical Research industry, and institutional ownership is very high. Analysts widely rate NAMS as a Buy, with …

NewAmsterdam Pharma to Host Investor Day on August 5, 2026

NewAmsterdam Pharma (Nasdaq: NAMS) announced it will host an Investor Day for analysts and investors on August 5, 2026, in New York City, featuring members of its management team. The event will include a live webcast and will focus on the company's progress in …

Unibail-Rodamco-Westfield (UNBLF) (H1 2026) Earnings Call Highlights: Record Low Vacancy and ...

This article first appeared on GuruFocus. Revenue (NRI) Growth: Like-for-like Net Rental Income (NRI) increased 4.5%, driven by a 3.9% rise in Europe and a 6.7% rise in US flagship assets. EBITDA Growth: Like-for-like EBITDA grew 5.3% year-on-year. Tenant Sales Growth: Tenant sales increased …

Wedbush Adjusts Damora Therapeutics Price Target to $40 From $35, Maintains Outperform Rating

Wedbush has increased its price target for Damora Therapeutics (DMRA) to $40 from $35, while reiterating an Outperform rating. The company currently holds an average rating of Buy from analysts, with a mean price target of $44.11.

NewAmsterdam Pharma to Discuss Cholesterol Drug at Aug. 5 Event

NewAmsterdam Pharma (Nasdaq: NAMS) will host an Investor Day on August 5, 2026, in New York City to discuss its late-stage cholesterol-lowering drug, obicetrapib. The event will feature presentations from the company's leadership and will cover ongoing Phase 3 programs like the PREVAIL cardiovascular …

NewAmsterdam Pharma (NAMS) Projected to Announce Earnings on Wednesday

NewAmsterdam Pharma Company N.V. Revenue Breakdown – GETTEX:KH6

NewAmsterdam Pharma Company N.V. (GETTEX:KH6) generated 19.16 million EUR in revenue last year, primarily from its Transformative Therapies for Cardio-metabolic Diseases segment. This represents a decrease from the 44.01 million EUR reported in the previous year. The company's largest revenue contribution came from Italy.

FGNX|FG Nexus Ord Shs|Price:6.800|Chg%:-0.160

This article provides a stock score and comprehensive analysis for FG Nexus Ord Shs (FGNX) by TradingKey, although it notes insufficient data to generate a score for FGNX itself. It details the methodology behind TradingKey's stock scoring system, covering financial health, valuation, earnings forecasts, …

We Think Damai Entertainment Holdings' (HKG:1060) Profit Is Only A Baseline For What They Can Achieve

Jefferies Initiates Coverage on Damora Therapeutics With Buy Rating, $50 Price Target

Jefferies has initiated coverage on Damora Therapeutics (DMRA) with a Buy rating and a $50 price target. This new rating is higher than the current average analyst rating of Buy with a mean price target of $44.11 for Damora Therapeutics, according to FactSet.

NewAmsterdam Pharma Company NV (NAMS) Valuation: PE, PB & Fair Value Analysis

NewAmsterdam Pharma Company NV (NAMS) currently has a valuation score of 6.93, placing it in the lower quartile of the Biotechnology & Medical Research industry. The company's P/E ratio stands at -16.99, indicating a significant deviation from its recent high and low P/E values. …

NewAmsterdam Pharma Company NV (NAMS) Income Statement

This article presents the quarterly and annual income statements for NewAmsterdam Pharma Company NV (NAMS), providing detailed financial figures such as revenue, operating expenses, net income, and earnings per share. It also includes FAQs explaining how to interpret income statements and key metrics for …

FG Nexus Inc. Revenue Breakdown – NASDAQ:FGNX

FG Nexus Inc. (NASDAQ:FGNX) generated $2.40 million USD in revenue last year, with its top-performing segment, Digital Assets, contributing $1.48 million USD. The majority of the company's revenue, $2.41 million USD, originated from the United States, although this was a decrease from $17.35 million …

NAMS|NewAmsterdam Pharma Company NV|Price:29.640|Chg%:-0.910

NewAmsterdam Pharma Company NV (NAMS) is trading at $29.64, down 2.98%. The company, which specializes in therapies for cardiometabolic diseases, has strong fundamentals and high growth potential, with analysts rating it a "Buy." Despite recent market underperformance, its valuation is considered fair, and institutional …